Form 8-K

8-K — Century Therapeutics, Inc.

Accession: 0001104659-26-113055

Filed: 2026-10-02

Period: 2026-10-02

CIK: 0001850119

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2626840d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2626840d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2626840d1_ex99-2.htm)

GRAPHIC (tm2626840d1_ex99-2img001.jpg)

GRAPHIC (tm2626840d1_ex99-2img002.jpg)

GRAPHIC (tm2626840d1_ex99-2img003.jpg)

GRAPHIC (tm2626840d1_ex99-2img004.jpg)

GRAPHIC (tm2626840d1_ex99-2img005.jpg)

GRAPHIC (tm2626840d1_ex99-2img006.jpg)

GRAPHIC (tm2626840d1_ex99-2img007.jpg)

GRAPHIC (tm2626840d1_ex99-2img008.jpg)

GRAPHIC (tm2626840d1_ex99-2img009.jpg)

GRAPHIC (tm2626840d1_ex99-2img010.jpg)

GRAPHIC (tm2626840d1_ex99-2img011.jpg)

GRAPHIC (tm2626840d1_ex99-2img012.jpg)

GRAPHIC (tm2626840d1_ex99-2img013.jpg)

GRAPHIC (tm2626840d1_ex99-2img014.jpg)

GRAPHIC (tm2626840d1_ex99-2img015.jpg)

GRAPHIC (tm2626840d1_ex99-2img016.jpg)

GRAPHIC (tm2626840d1_ex99-2img017.jpg)

GRAPHIC (tm2626840d1_ex99-2img018.jpg)

GRAPHIC (tm2626840d1_ex99-2img019.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2626840d1_8k.htm · Sequence: 1

false

0001850119

2026-10-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 2, 2026

Century Therapeutics, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-40498

84-2040295

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

North 38th Street, 12th Floor

Philadelphia, Pennsylvania

19104

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name

of Exchange on Which Registered

Common Stock, par value $0.0001 per share

IPSC

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure

On October 2, 2026, Century Therapeutics, Inc. (the “Company”)

issued a press release announcing that nonclinical data from the Company’s iPSC-derived cell therapy platform was presented at the

European Association for the Study of Diabetes (“EASD”) held on October 2, 2026 in Milan, Italy. The full text of the press

release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01 (including Exhibit 99.1)

is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended

(the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference

in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference

in such filing.

Item 8.01

Other Events

A copy of the slides presented by the Company at EASD is filed as Exhibit

99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement

or amend the materials attached hereto as Exhibit 99.2.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit

No.

Document

99.1

Press Release of Century Therapeutics, Inc., dated October 2, 2026

99.2

European Association for the Study of Diabetes Presentation Slides of Century Therapeutics, Inc.,

dated October 2, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.

By:

/s/ Brent Pfeiffenberger, Pharm.D., M.B.A.

Name:

Brent Pfeiffenberger, Pharm.D., M.B.A.

Title:

President, Chief Executive Officer and Chairman of the Board of Directors

Date: October 2, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2626840d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Century Therapeutics'

CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Data demonstrated

scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived

islet replacement therapy for type 1 diabetes

CNTY-813 IND

submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027

PHILADELPHIA, October 2nd,

2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (“Century”, NASDAQ: IPSC), a biotechnology company developing induced

pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes (T1D) and other autoimmune diseases, today announced the presentation

of nonclinical data for CNTY-813, Century's iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0. Data were

presented in an oral presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD)

in Milan, Italy.

In a study lasting over eleven months,

updated data demonstrated CNTY-813 maintained glycemic control in a diabetic mouse model until CNTY-813’s graft removal. New data

further highlighted CNTY-813’s anticipated readiness for clinical testing via demonstration of drug product consistency across

five clinical-scale runs, glycemic control in a diabetic mouse model after extended drug product cold storage, and successful engraftment

of CNTY-813 via the intended clinical route of administration.

“The data presented at EASD build

on the nonclinical package we presented at ADA in June and highlight our continued execution on bringing CNTY-813 into the clinic,”

said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “Following our pre-IND meeting, in which

we reached general alignment with FDA on our nonclinical package, Phase 1 manufacturing process and proposed Phase 1/2 trial design,

we remain on track to submit the CNTY-813 IND in the fourth quarter of this year with initial clinical data anticipated in the second

half of 2027.”

New Nonclinical Data Highlights

Glycemic control sustained until

graft removal in diabetic mice

· Allo-Evasion™ 5.0-edited

CNTY-813 islets rapidly restored normoglycemia in streptozotocin-induced diabetic mice and

maintained glycemic control until graft removal, demonstrating clear pharmacological activity.

The study lasted over eleven months.

· All streptozotocin-induced diabetic

mice administered with CNTY-813 achieved normoglycemia.

· CNTY-813 islets showed glucose-stimulated

insulin secretion potency similar to primary islets.

Phase 1 clinical manufacturing

process produced consistent product across five clinical-scale batches

· Five clinical-scale batches from

Century's Good Manufacturing Practice Master Cell Bank produced consistent final product

profiles.

· The 29-day process exceeded purity

criteria at every stage.

Liver portal vein delivery in

rats resulted in successful engraftment supporting the planned clinical route of administration

· In rats, CNTY-813 islets were identified

engrafted in the liver at one month post-transplant.

· Engrafted islets stained positive

for chromogranin A, an endocrine cell marker, and for insulin, confirming they retained islet

endocrine and beta cell identity after delivery.

Clinical-scale product remained

functional after 96 hours of cold storage, supporting future clinical supply chain

· Mice transplanted with clinical-scale

islets after 96 hours of cold storage normalized blood glucose within 30 days and maintained

normoglycemia through three months of follow-up.

· By one month post-transplant, glucose

tolerance was indistinguishable from normoglycemic controls.

Grant Welstead,

Ph.D., Senior Vice President, Head of Research at Century, delivered the presentation, titled “CNTY-813: Scalable Production of

Allo-Evasion™ 5.0-Engineered iPSC-Derived Islets for Off-the-Shelf Cell Therapies” (Presentation 225), on Friday, October

2, 2026, in Session OP 39, “Beta cells on demand: stem cells to beta cell therapy,” held from 10:00 to 11:00 a.m. Central

European Summer Time in Paris Hall. The presentation is available in the Scientific Resources section of the Science page on Century's

website at Events and Presentations | Century Therapeutics.

Upcoming CNTY-813 Milestones

· Investigational New Drug (IND)

submission (4Q 2026): Century expects to submit an Investigational New Drug application

for CNTY-813 in the fourth quarter of 2026, subject to completion of remaining IND-enabling

studies.

· Initial clinical data (2H 2027):

Initial safety and early efficacy data from the first-in-human CNTY-813 study are anticipated

in the second half of 2027.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC)

is a biotechnology company advancing a pipeline of iPSC-derived cell therapies with the potential to meaningfully address autoimmune

diseases, including T1D, and cancer. Century's therapies are derived from its iPSC cell foundry and leverage its novel immune evasion

engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient

access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on

Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking

statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of

1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present

facts or current conditions, including but not limited to, statements regarding our timing and expectations for regulatory submissions,

nonclinical and clinical development, including CNTY-813's IND submission and expected data readout in the second half of 2027, and our

financial resources and expected cash runway, are forward-looking statements. These statements involve known and unknown risks, uncertainties

and other important factors that may cause our actual results, performance, or achievements to be materially different from any future

results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking

statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,”

“aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,”

“contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential”

or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release

are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future

events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking

statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some

of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described

more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available

at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. Except as required by applicable

law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information,

future events, changed circumstances or otherwise.

For More Information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance

investor.relations@centurytx.com

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: tm2626840d1_ex99-2.htm · Sequence: 3

Exhibit 99.2

CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research

2 Disclosures Presenter G. Grant Welstead, PhD Relevant Financial Relationship • Employee, Century Therapeutics Presentation Information • This presentation describes preclinical research related to CNTY - 813, an investigational iPSC - derived islet cell therapy for T1D • The content is intended for scientific and educational discussion • No clinical recommendations will be made 2

3 This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present fa cts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines and the initial safety and efficacy profiles of CNTY - 813 and s tatements regarding our preclinical development programs, including preclinical data, development plans and timelines, are forward - looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future res ults, performance or achievements expressed or implied by the forward - looking statements. In some cases, you can identify forward - looking statements by terms such as “may,” “m ight,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential ” o r “continue” or the negative of these terms or other similar expressions. The forward - looking statements in this presentation are only predictions. We have based these forward - looking state ments largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and result s o f operations. These forward - looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which c ann ot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates th rou gh development activities, preclinical studies, and clinical trials; our ability to progress CNTY - 813 through clinical development; our ability to meet development milestones on an ticipated timelines; uncertainties inherent in the results of preliminary data, pre - clinical studies and earlier - stage clinical trials, which may not be predictive of final results or the results of later - stage clinical trials; our ability to obtain clearance of our future Investigational New Drug (IND) or Clinical Trial Application (CTA) submissions and commence and compl ete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product c and idates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trad e d isputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of ou r product candidates, including third parties conducting our clinical trials as well as third - party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our a bil ity to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” sect ion of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward - looking statements as predictions of futu re events. The events and circumstances reflected in our forward - looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward - looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not pos sib le for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward - lo oking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Forward - looking statements

4 Islet transplantation provides a potentially curative therapy for T1D Supply and chronic immunosuppression limit the broader use of T1D cell therapies Islet cell transplantation provides potential for curative therapy in T1D In T1D, islet cells are destroyed Healthy islet cells produce insulin (green) In T1D, islet cells are destroyed Insulin independence following pancreatic islet transplantation Insulin independence achieved for one year in ~70% of patients receiving allogenic cadaveric islet transplantation 1 CNTY - 813: Century’s islets with Allo - Evasion TM 5.0 are designed to address key challenges in T1D cell therapy 4 Source: Marfil - Garza et al. 2022; Pancreatic islet transplantation in type 1 diabetes: 20 - year experience from a single - centre cohort in Canada 1. Approximately 1500 patients reported in https://www.citregistry.org/system/files/CITR%2012th%20Allograft%20Report_2025_Final.pdf

5 • Scalable iPSC - derived islet manufacturing • Reproducible islet differentiation • Clinical manufacturing process from GMP MCB Differentiation platform Functional islets ALLO - EVASION 5.0 Scalable manufacturing, islet function, and immune - evasive engineering address key barriers for T1D cell replacement • Glucose - responsive insulin secretion • In vivo glucose control in diabetic mice • No safety events observed to date in preclinical models – i.e., tumor formation • T cell protection • NK cell protection • Reduced humoral immune clearance CNTY - 813 design integrates key capabilities for off - the - shelf T1D cell therapy

6 6 Stage 1 Stage 2 Stage 4 Stage 5 Stage 6 Stage 3 Generation of islets with a 29 - day defined process High purity and reproducible across batches iPSC Definitive Endoderm Primitive Gut Tube Pancreatic Progenitor II Endocrine β Cell Pancreatic Progenitor I Stage 1 Definitive Endoderm Stage 4 Pancreatic Progenitor II Stage 6 Islet Endocrine Stage 6 Beta Cell 97.3 (20) 98.2 (24) 95.9 (32) 60.2 (32) Mean (n) Consistent Differentiation Surpassed necessary purity at every stage >95% Endocrine 50 – 60% Beta Cells (Insulin Producing) • Dotted lines: Success criteria • N are independent batches. • Source: Company data on file

7 CNTY - 813 islets contain defined, terminally differentiated endocrine cell populations Population Enriched Markers: β - cell: INS, NKX6.1; ⍺ - cell: GCG,ARX; δ - cell: SST; Exocrine/Ductal: KRT19; FEV+ Islet Cell: FEV+SLC18A1+ Diff. Stage: scRNAseq Cell Cycle Annotations scRNAseq Cell Type Annotations • CNTY - 813 manufacturing achieves a defined islet endocrine composition, with beta cells as the predominant population • Data is consistent with cell cycle exit on par with primary islets by end of manufacture (>98% G1 phase identity) iPSC 1 2 3 4 5 6 Frequency Population (30,151 total) 66.3% β cells 26.4% FEV+ Islet Cells 5.5% ⍺ cells 0.8% δ cells 1.0% Exocrine/Ductal CNTY - 813 data represents four combined end - of - process samples

8 CNTY - 813 islet cells demonstrate robust glucose - responsive function Nonclinical Potency Stimulation Index Total Insulin Content Glucose Stimulated Insulin Secretion iPSC- Islets Primary Islets 0 10000 20000 30000 40000 u I U I n s u l i n / 1 E 6 C e l l s 2mM Glucose 20mM Glucose ∆ GSIS i P S C - I s l e t s P r i m a r y I s l e t s 0 5 10 15 G l u c o s e S t i m u a l t i o n I n d e x ( 2 0 m M g l u c o s e / 2 m M g l u c o s e ) Glucose Stimulation Index Mean +/ - SD is shown in graphs Source: Company data on file

9 CNTY - 813 provided durable glycemic control for >11 months, with reversal after graft removal demonstrating clear pharmacological activity CNTY - 813 islets rapidly restored normoglycemia in STZ - induced diabetic mice Nonclinical Potency 0 20 40 60 80 100 120 0 100 200 300 400 500 600 Time (min) B l o o d G l u c o s e ( m g / d L ) Diabetic Control CNTY-813 (SRC) (5M) - 12 weeks CNTY-813 (SRC) (5M) - 49 weeks Glucose Control Non - Fasted Blood Glucose Glucose Tolerance Test Mean +/ - SD CNTY - 813 resected STZ = Streptozotocin | SRC = Sub renal capsule implantation, Gray shaded area = normal blood glucose range Source: Company data on file

10 CNTY - 813 grafts maintain endocrine identity with no evidence of tumorigenesis in mouse models Endocrine graft identity over time INS+ (green) CHGA+ (orange) Merged (yellow) Ki67+ (pink) DAPI (blue) INS: Insulin stain; CHGA: CHGA stain; Ki67: Stain for human and mouse Ki67; DAPI: nuclear stain 4 weeks 8 weeks 2 weeks 24 weeks 200µm x Endocrine graft morphology maintained x Stable Insulin and low Ki67 staining post engraftment x No tumorigenesis observed in >140 mice with >3 - month follow up (>1B cells infused) x All CNTY - 813 infused mice achieve normoglycemia Source: Company data on file

11 CNTY - 813 is engineered to evade T cell, NK cell, and humoral responses b2M KO (HLA - I) CIITA KO (HLA - II) CD8 + T Cell CD4 + T Cell Pan NK Inhibitory ligand Fc NK cell No HLA - I Prevents recognition by CD8+ cells T cells No HLA - II Prevents recognition by CD4+ cells T cells IgG Cleavage Reduces Fc binding and humoral activity CD300a TASR Ligand Inhibits NK cell activation Protection from T cells NK cells Humoral Immunity ALLO - EVASION 5.0 Insertion of CD300a TASR pan - NK inhibitory ligand 1, 2 Insertion of cell - surface enzyme to degrade IgG antibodies 3 Deletion of HLA - I Deletion of HLA - II 1. https://www.centurytx.com/wp - content/uploads/ASH_Welstead_Universal - Protection - of - Allogenic - T - Cells - Final.pdf 2. https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013436/518079/Universal - Protection - of - Allogeneic - T - Cell 3. Peraro et al, Mol. Therapy 2021, 29(12), 3398 - 3409; https://pmc.ncbi.nlm.nih.gov/articles/PMC8636170

12 CNTY - 813 demonstrated protection from multiple immune effector mechanisms Reduced NK Cell Activation NK - CELL Protection IgG Cleavage Protected from phagocytosis Rapid IgG Cleavage Reduced Antibody - Dependent Phagocytosis (ADCP) 01 02 03 Reduced NK Cell Cytotoxicity 0.25:1 0.5:1 1:1 2:1 10 20 30 40 E:T ratio C D 1 0 7 a + ( % ) WT DKO CTNY-813 NK Activation **** **** **** **** Donor 1 Donor 2 0 25 50 75 100 125 NK Cell Donor P e r c e n t S u r v i v a l ( % ) DKO CNTY-813 ✱✱✱ ✱✱✱ Significant reduction in intact IgG after 1 hour in cleavage assay Protection from ADCP achieved against an antibody targeting EpCAM CNTY - 813 did not activate or get cleared by NK cells CNTY - 813 degraded IgG antibodies in vitro CNTY - 813 protection from Ab - mediated phagocytosis *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 Source: Company data on file

13 Humanized Mouse Engrafted with Healthy Donor PBMCs Employing a humanized mouse model to study allogeneic graft rejection • Functional human T cells without GvHD (MHC DKO) – Supports longer study durations • Supports engraftment and survival of human NK cells (TgHu - IL15) • Testing of allo - rejection mediated by human T cells and NK cells ( huPBMCs ) NSG - MHC I/II DKO +/+ NSG - Tg (Hu - IL15) +/+ X No GvHD Human NK cell support Human immune - cell engraftment supports functional testing of allo - rejection in vivo

14 Allo - Evasion 5.0 maintained CNTY - 813 Glucose Stimulated Insulin Secretion and GTT performance in vivo1 Allo - EvasionTM 5.0 protected CNTY - 813 from rejection in a humanized mouse model Glucose Stimulation Index Glucose Tolerance Test (GTT) (11 weeks post - islet infusion) Reduced function with PBMC engraftment Maintained function with PBMC engraftment 0 7 14 21 28 35 42 49 0 5 10 15 Days Post Transplant G l u c o s e - S t i m u l a t e d I n s u l i n S e c r e t i o n I n d e x ( C - p e p t i d e i n d u c t i o n o v e r b a s e l i n e ) Unedited Islets + PBMCs Unedited Islets Allo - Rejection 0 7 14 21 28 35 42 49 0 5 10 15 Days Post Transplant G l u c o s e - S t i m u l a t e d I n s u l i n S e c r e t i o n I n d e x ( C - p e p t i d e i n d u c t i o n o v e r b a s e l i n e ) CNTY-813 Allo-Evasion 5.0 Islets + PBMCs CNTY-813 Allo-Evasion 5.0 Islets Mean ± SEM TM TM 0 30 60 90 120 0 200 400 600 Time (min.) B l o o d G l u c o s e ( m g / d L ) Unedited Islets + PBMCs Unedited Islets 0 30 60 90 120 0 200 400 600 Time (min.) B l o o d G l u c o s e ( m g / d L ) Allo-Evasion 5.0 Islets + PBMCs Allo-Evasion 5.0 Islets Mean ± SD TM TM Unedited Islets Allo - Evasion TM 5.0 Islets Unedited Islets Allo - Evasion TM 5.0 Islets 1. Humanized mouse model includes functional human T cells without GvHD (MHC KO) and TgHuIL - 15 to support functional NK cell eng raftment and survival Source: Company data on file

15 Phase 1 clinical manufacturing process established and executed from MCB across multiple independent batches MCB Thaw iPSC Expansion Bioreactor Differentiation Cryopreserved Intermediate Post - Thaw Maturation Final Fresh Product Consistent final product flow cytometry profiles across 5 clinical - scale batches Source: Company data on file Clinical Scale Run CHGA+ INS+NKX6.1+ Ki67+

16 Successful CNTY - 813 engraftment in rat livers via portal vein injection Vehicle Control CNTY - 813 – H&E CNTY - 813 – IF PV HA BD HA HA BD BD CNTY - 813 BD HA BD CNTY - 813 BD HA BD DAPI Chromogranin A Insulin CNTY - 813 CNTY - 813 aggregates are identified in the liver at 1 - month post - transplant Islets stain positive for chromogranin A and Insulin PV= Portal Venule; HA= Hepatic Artery; BD= Bile Duct; CV= Central Vein Source: Company data on file

17 IPGTT= Intraperitoneal Glucose Tolerance Test Source: Company data on file Clinical - scale islets restored durable normoglycemia after 96 - hours in cold storage Clinical - scale product with 96 - hour cold storage stability Islets manufactured at clinical scale retained full functionality after 96 - hours in cold storage solution Rapid restoration of glycemic control Transplanted mice normalized blood glucose within 30 days post - transplant and maintain stable normoglycemia through 3 months of follow - up Glucose tolerance equivalent to healthy controls IPGTT glucose clearance in treated mice was indistinguishable from normoglycemic controls by 1 - month post - transplant

18 CNTY - 813 demonstrated reproducible differentiation, durable glucose control, and immune - evasive function in preclinical models • Reproducible, bioreactor - enabled differentiation from GMP MCB • Phase 1 clinical manufacturing process established • CNTY - 813 specs: – >95% islet endocrine – >50% beta cell identity Differentiation platform Functional islets ALLO - EVASION 5.0 • GSIS potency similar to primary islets • Rapid and durable glucose control observed in diabetic mice • Maintained graft identity with a favorable safety profile • Engineered to reduce T - cell, NK - cell, and humoral immune recognition • Protection from NK and humoral clearance demonstrated • Preserved graft function under alloimmune pressure in vivo These data support the development of CNTY - 813 as a potentially broadly accessible, off - the - shelf cell therapy for Type 1 Diabetes

19 Acknowledgements Mike Brehm & Lab – UMASS Chan School of Medicine and Diabetes Center of Excellence 19 Entire Century Team

GRAPHIC

Filename: tm2626840d1_ex99-2img001.jpg · Sequence: 7

Binary file (156581 bytes)

Download tm2626840d1_ex99-2img001.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img002.jpg · Sequence: 8

Binary file (123314 bytes)

Download tm2626840d1_ex99-2img002.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img003.jpg · Sequence: 9

Binary file (388724 bytes)

Download tm2626840d1_ex99-2img003.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img004.jpg · Sequence: 10

Binary file (182030 bytes)

Download tm2626840d1_ex99-2img004.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img005.jpg · Sequence: 11

Binary file (143216 bytes)

Download tm2626840d1_ex99-2img005.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img006.jpg · Sequence: 12

Binary file (140564 bytes)

Download tm2626840d1_ex99-2img006.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img007.jpg · Sequence: 13

Binary file (166590 bytes)

Download tm2626840d1_ex99-2img007.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img008.jpg · Sequence: 14

Binary file (114130 bytes)

Download tm2626840d1_ex99-2img008.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img009.jpg · Sequence: 15

Binary file (153088 bytes)

Download tm2626840d1_ex99-2img009.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img010.jpg · Sequence: 16

Binary file (190513 bytes)

Download tm2626840d1_ex99-2img010.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img011.jpg · Sequence: 17

Binary file (149797 bytes)

Download tm2626840d1_ex99-2img011.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img012.jpg · Sequence: 18

Binary file (151368 bytes)

Download tm2626840d1_ex99-2img012.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img013.jpg · Sequence: 19

Binary file (133804 bytes)

Download tm2626840d1_ex99-2img013.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img014.jpg · Sequence: 20

Binary file (159074 bytes)

Download tm2626840d1_ex99-2img014.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img015.jpg · Sequence: 21

Binary file (143031 bytes)

Download tm2626840d1_ex99-2img015.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img016.jpg · Sequence: 22

Binary file (206561 bytes)

Download tm2626840d1_ex99-2img016.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img017.jpg · Sequence: 23

Binary file (164091 bytes)

Download tm2626840d1_ex99-2img017.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img018.jpg · Sequence: 24

Binary file (177562 bytes)

Download tm2626840d1_ex99-2img018.jpg

GRAPHIC

Filename: tm2626840d1_ex99-2img019.jpg · Sequence: 25

Binary file (61144 bytes)

Download tm2626840d1_ex99-2img019.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 27

v3.26.3

Cover

Oct. 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 02, 2026

Entity File Number

001-40498

Entity Registrant Name

Century Therapeutics, Inc.

Entity Central Index Key

0001850119

Entity Tax Identification Number

84-2040295

Entity Incorporation, State or Country Code

Entity Address, Address Line One

North 38th Street

Entity Address, Address Line Two

12th Floor

Entity Address, City or Town

Philadelphia

Entity Address, State or Province

Entity Address, Postal Zip Code

19104

City Area Code

267

Local Phone Number

817-5790

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

IPSC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration